Related Experiment Video
Updated: May 1, 2026
11:28
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
40.7K
High-Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance
1Department of Infectious Diseases, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Alimentary Pharmacology & Therapeutics
|July 16, 2025
Summary
Hepatitis B virus (HBV) integration patterns influence hepatitis B surface antigen (HBsAg) loss in chronic hepatitis B (CHB) patients. Fewer HBV integration breakpoint types correlate with higher HBsAg loss rates after pegylated interferon therapy.
Area of Science:
- Hepatology
- Virology
- Genomics
Background:
- Hepatitis B virus (HBV) integration profiles and their link to hepatitis B surface antigen (HBsAg) loss are not well understood.
- Chronic hepatitis B (CHB) management aims for HBsAg loss, a key indicator of functional cure.
Purpose of the Study:
- To investigate HBV integration patterns in virally suppressed CHB patients.
- To determine the association between HBV integration and HBsAg loss following antiviral therapy.
Main Methods:
- Analysis of paired liver biopsies from 45 CHB patients in the Anchor study (NCT02327416).
- High-throughput detection of viral integration.
- Primary endpoint: HBsAg loss at Week 96.
Main Results:
- Clonal expansion at baseline correlated with nucleos(t)ide analogue (NUC) treatment duration, ALT, and AST levels.
- Patients with <28 HBV integration breakpoint types showed significantly higher HBsAg loss rates at Weeks 48 and 96 with Peg-IFN-based therapy.
- No association found between clonal expansion and HBsAg, HBcrAg, HBV RNA, or cccDNA levels at baseline.
Conclusions:
- NUC treatment duration and ALT/AST levels are linked to clonal expansion in suppressed CHB patients.
- A lower number of HBV integration breakpoint types may predict higher HBsAg loss rates with Peg-IFN therapy.
- Baseline HBV integration patterns could guide treatment decisions for achieving HBsAg loss.
